Short term fluvastatin treatment lowers serum asymmetric dimethylarginine levels in patients with metabolic syndrome

International Heart Journal

Volumn 49, Issue 3, 2008, Pages 303-311

  Oguz, Aytekin ^a   Uzunlulu, Mehmet ^a,b  

^a GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b NONE   (Turkey)

Author keywords

Asymmetric dimethylarginine; Fluvastatin; Metabolic syndrome

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; INSULIN; N(G),N(G) DIMETHYLARGININE; ORAL ANTIDIABETIC AGENT;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETES MELLITUS; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTHESIS; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; STATISTICAL SIGNIFICANCE; TABLET FORMULATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADULT; ARGININE; CHOLESTEROL; ENDOTHELIUM, VASCULAR; FATTY ACIDS, MONOUNSATURATED; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INDOLES; MALE; METABOLIC SYNDROME X; MIDDLE AGED; TREATMENT OUTCOME;

EID: 49449118649     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.303     Document Type: Article

References (35)

1. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100. (Review)
2. Tonstad S, Hjermann I. A high risk score for coronary heart disease is associated with the metabolic syndrome in 40-year-old men and women. J Cardiovasc Risk 2003; 10: 129-35.
3. Solymoss BC, Bourassa MG, Lespérance J, et al. Incidence and clinical characteristics of the metabolic syndrome in patients with coronary artery disease. Coron Artery Dis 2003; 14: 207-12.
4. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26. (Review)
5. Liao JK. Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol. Am J Cardiol 2005; 96: 24F-33. (Review)
6. Vallace P, Leone A, Calver A, Collier J, Montada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20: S60-2.
7. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032-7. (Review)
8. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001; 88: 1201-3.
9. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 2005; 46: 518-23.
10. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842-7.
11. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for conary heart disease: results from the multicenter Coronary Artery Risk Determination Investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J 2006; 152: 493. e1-8.
12. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005; 47: 201-10. (Review)
13. Ballantyne CM, Pazzucconi F, Pintó X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clin Ther 2001; 23: 177-92.
14. Grundy SM, Cleeman JI, Daniels SR, et al; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/ National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. (Review)
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
16. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997; 20: 1744-66. (Review)
17. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 2003; 59: 824-33. (Review)
18. Tesfamariam B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am J Cardiovasc Drugs 2006; 6: 115-20. (Review)
19. Päivä H, Laakso J, Lehtimäki T, Isomustajärvi M, Ruokonen I, Laaksonen R. Effect of high-dose treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 2003; 41: 219-22.
20. Valkonen VP, Laakso J, Päivä H, et al. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl 2003; 4: 19-22.
21. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine patients with hypercholesterolemia. Am J Cardiol 2004; 94: 157-61.
22. Stühlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-6.
23. Chen JW, Hsu NW, Wu TC, Li SJ, Chang MS. Long-term angiotensi-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol 2002; 90: 974-82.
24. Asagami T, Abbasi F, Stuelinger M, et al. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 2002; 51: 843-6.
25. Post MS, Verhoeven MO, van der Mooren MJ, Kenemans P, Stehouwer CD, Teerlink T. Effect of hormone replacement therapy on plasma levels of the cardiovascular risk factor asymmetric dimethylarginine: a randomized, placebo-controlled 12-week study in healthy early postmenopausal women. J Clin Endocrinol Metab 2003; 88: 4221-6.
26. Maas R. Pharmacotherapies and their influence on asymmetric dimethylarginine-(ADMA). Vasc Med 2005; 10: S49-57. (Review)
27. Zhang WZ, Venardos K, Chin-Dusting J, Kave DM. Adverse effects of cigarette smoke on NO bioavailability: role of arginine metabolism and oxidative stress. Hypertension 2006; 48: 278-85.
28. Ascaso J, Gonzalez Santos P, Hernandez Mijares A, et al. Management of dyslipidemia in the metabolic syndrome: recommendations of Spanish HDL-Forum. Am J Cardiovasc Drugs 2007; 7: 39-58. (Review)
29. Ilerigelen B, Uresin Y, San M, et al; TULIPS Investigators. Efficacy and safety of extended-release fluvastatin in Turkish patients with hypercholesterolaemia: TULIPS (Turkish Lipid Study). Curr Med Res Opin 2007; 23: 1093-102.
30. Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW; STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndrome. Am J Cardiol 2005; 95: 360-6.
31. Zambon A, Pauletto P, Crepaldi G Review article: the metabolic syndrome - a chronic cardiovascular inflammatory condition. Aliment Pharmacol Ther 2005; 22: 20-3, (Review)
32. Guven A, Cetinkaya A, Aral M, et al. High-sensitivity C-reactive protein in patients with metabolic syndrome. Angiology 2006; 57: 295-302.
33. Nissen SE, Tuzcu EM, Schoenhagen P, et al; REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
34. Devaraj S, Chan E, Jialal I. Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 2006; 91: 4489-96.
35. Yip HK, Wu CJ, Hang CL, et al. Levels and values of inflammatory markers in patients with angina pectoris. Int Heart J 2005; 46: 571-81.